Status:
RECRUITING
Real World Study in Greek Patients with BPH for Disease Control and QoL Under FDC Treatment with Solifenacin/Tamsulosin.
Lead Sponsor:
Elpen Pharmaceutical Co. Inc.
Conditions:
Benign Prostatic Hyperplasia
Eligibility:
MALE
18-100 years
Brief Summary
Benign prostatic hyperplasia (BPH) is an age-related progressive condition of the prostate gland that results in an increase in prostate size. Although the "normal" prostate in adult men usually has ...
Detailed Description
The only clearly defined risk factors for BPH are age and the presence of elevated androgens in the blood. But there are other factors that can influence the prevalence of clinical disease such as met...
Eligibility Criteria
Inclusion
- Male adult patient with moderate to severe symptoms of BPH receiving monotherapy and not responding adequately.
- Male adult patient with BPH who has fully understood the study procedures and signed an informed consent form.
Exclusion
- \-
Key Trial Info
Start Date :
October 23 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2025
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT06528613
Start Date
October 23 2024
End Date
September 30 2025
Last Update
March 12 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Second Department of Urology, Sismanoglio Hospital, Athens, Greece.
Athens, Greece, Greece, 15126
2
Department of Urology, Venizelio General Ηospital
Heraklion, Greece, Greece, 71409
3
Department of Urology, General Hospital of Messinia
Kalamata, Greece, Greece, 24100
4
Department of Urology, General Hospital of Larissa
Larissa, Greece, Greece, 41221